The Affiliated Hospital of Xuzhou Medical University

No.99, Huaihai W. Road, Quanshan District, Xuzhou, 江苏省, China

Clinical Trials

13 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

30.0%

Phase 1

18.6%

Phase 2

15.7%

Phase 4

10.0%

Early Phase 1

5.7%

Trial Status Distribution

Active, not recruiting

5.7%

Completed

18.6%

Not yet recruiting

12.9%

Recruiting

38.6%

Unknown

22.9%

Withdrawn

1.4%

Clinical Trials

Trials sponsored by this organization (70)

Effect of transcutaneous acupoint electrical stimulation assisted general anesthesia on postoperative fatigue in patients undergoing laparoscopic radical gastrectomy for gastric cancer

Phase 1

Recruiting

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Phase 1

Not yet recruiting

interventional

May 202620 participants

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

Not Applicable

Recruiting

interventional

Mar 20266 participants

Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2

Recruiting

interventional

Mar 202630 participants

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

Phase 1

Withdrawn

interventional

Mar 202615 participants

Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial

Phase 4

Completed

interventional

Dec 202560 participants

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Phase 4

Not yet recruiting

interventional

Nov 20251,160 participants

AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

Phase 1

Recruiting

interventional

Nov 202512 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations